PDGFR α antagonist

DRUG CLASS:

PDGFR α antagonist

News alerts, weekly reports and conference planners

Related drugs:

‹

›

No biomarker	Soft Tissue Sarcoma	No biomarker	Soft Tissue Sarcoma	olaratumab Sensitive: A1 - Approval olaratumab Sensitive : A1	olaratumab Sensitive: A1 - Approval olaratumab Sensitive : A1
No biomarker	Thymic Carcinoma	No biomarker	Thymic Carcinoma	lenvatinib Sensitive: A1 - Approval lenvatinib Sensitive : A1	lenvatinib Sensitive: A1 - Approval lenvatinib Sensitive : A1
No biomarker	Thyroid Gland Follicular Carcinoma	No biomarker	Thyroid Gland Follicular Carcinoma	lenvatinib Sensitive: A1 - Approval lenvatinib Sensitive : A1	lenvatinib Sensitive: A1 - Approval lenvatinib Sensitive : A1
No biomarker	Thyroid Gland Hurthle Cell Carcinoma	No biomarker	Thyroid Gland Hurthle Cell Carcinoma	lenvatinib Sensitive: A1 - Approval lenvatinib Sensitive : A1	lenvatinib Sensitive: A1 - Approval lenvatinib Sensitive : A1
No biomarker	Thyroid Gland Papillary Carcinoma	No biomarker	Thyroid Gland Papillary Carcinoma	lenvatinib Sensitive: A1 - Approval lenvatinib Sensitive : A1	lenvatinib Sensitive: A1 - Approval lenvatinib Sensitive : A1
No biomarker	Endometrial Cancer	No biomarker	Endometrial Cancer	pembrolizumab + lenvatinib Sensitive: A1 - Approval pembrolizumab + lenvatinib Sensitive : A1	pembrolizumab + lenvatinib Sensitive: A1 - Approval pembrolizumab + lenvatinib Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	everolimus + lenvatinib Sensitive: A1 - Approval everolimus + lenvatinib Sensitive : A1	everolimus + lenvatinib Sensitive: A1 - Approval everolimus + lenvatinib Sensitive : A1
No biomarker	Thyroid Gland Carcinoma	No biomarker	Thyroid Gland Carcinoma	lenvatinib Sensitive: A1 - Approval lenvatinib Sensitive : A1	lenvatinib Sensitive: A1 - Approval lenvatinib Sensitive : A1
No biomarker	Hepatocellular Cancer	No biomarker	Hepatocellular Cancer	lenvatinib Sensitive: A1 - Approval lenvatinib Sensitive : A1	lenvatinib Sensitive: A1 - Approval lenvatinib Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	pembrolizumab + lenvatinib Sensitive: A1 - Approval pembrolizumab + lenvatinib Sensitive : A1	pembrolizumab + lenvatinib Sensitive: A1 - Approval pembrolizumab + lenvatinib Sensitive : A1
MSI-H/dMMR	Endometrial Cancer	MSI-H/dMMR	Endometrial Cancer	pembrolizumab + lenvatinib Sensitive: A2 - Guideline pembrolizumab + lenvatinib Sensitive : A2	pembrolizumab + lenvatinib Sensitive: A2 - Guideline pembrolizumab + lenvatinib Sensitive : A2
No biomarker	Clear Cell Renal Cell Carcinoma	No biomarker	Clear Cell Renal Cell Carcinoma	lenvatinib Sensitive: A2 - Guideline lenvatinib Sensitive : A2	lenvatinib Sensitive: A2 - Guideline lenvatinib Sensitive : A2
No biomarker	Biliary Tract Cancer	No biomarker	Biliary Tract Cancer	pembrolizumab + lenvatinib Sensitive: A2 - Guideline pembrolizumab + lenvatinib Sensitive : A2	pembrolizumab + lenvatinib Sensitive: A2 - Guideline pembrolizumab + lenvatinib Sensitive : A2
No biomarker	Clear Cell Renal Cell Carcinoma	No biomarker	Clear Cell Renal Cell Carcinoma	pembrolizumab + lenvatinib Sensitive: A2 - Guideline pembrolizumab + lenvatinib Sensitive : A2	pembrolizumab + lenvatinib Sensitive: A2 - Guideline pembrolizumab + lenvatinib Sensitive : A2
No biomarker	Cutaneous Melanoma	No biomarker	Cutaneous Melanoma	pembrolizumab + lenvatinib Sensitive: A2 - Guideline pembrolizumab + lenvatinib Sensitive : A2	pembrolizumab + lenvatinib Sensitive: A2 - Guideline pembrolizumab + lenvatinib Sensitive : A2
No biomarker	Kidney Cancer	No biomarker	Kidney Cancer	everolimus + lenvatinib Sensitive: A2 - Guideline everolimus + lenvatinib Sensitive : A2	everolimus + lenvatinib Sensitive: A2 - Guideline everolimus + lenvatinib Sensitive : A2
No biomarker	Kidney Cancer	No biomarker	Kidney Cancer	pembrolizumab + lenvatinib Sensitive: A2 - Guideline pembrolizumab + lenvatinib Sensitive : A2	pembrolizumab + lenvatinib Sensitive: A2 - Guideline pembrolizumab + lenvatinib Sensitive : A2
RET fusion	Lung Cancer	RET fusion	Lung Cancer	lenvatinib Sensitive: B - Late Trials lenvatinib Sensitive : B	lenvatinib Sensitive: B - Late Trials lenvatinib Sensitive : B
No biomarker	Small Cell Lung Cancer	No biomarker	Small Cell Lung Cancer	CS 2164 Sensitive: B - Late Trials CS 2164 Sensitive : B	CS 2164 Sensitive: B - Late Trials CS 2164 Sensitive : B
FGF21 elevation	Hepatocellular Cancer	FGF21 elevation	Hepatocellular Cancer	lenvatinib Sensitive: B - Late Trials lenvatinib Sensitive : B	lenvatinib Sensitive: B - Late Trials lenvatinib Sensitive : B
VEGFA elevation	Hepatocellular Cancer	VEGFA elevation	Hepatocellular Cancer	lenvatinib Resistant: B - Late Trials lenvatinib Resistant : B	lenvatinib Resistant: B - Late Trials lenvatinib Resistant : B
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	pembrolizumab + lenvatinib Sensitive: B - Late Trials pembrolizumab + lenvatinib Sensitive : B	pembrolizumab + lenvatinib Sensitive: B - Late Trials pembrolizumab + lenvatinib Sensitive : B
No biomarker	Hepatocellular Cancer	No biomarker	Hepatocellular Cancer	pembrolizumab + lenvatinib Sensitive: B - Late Trials pembrolizumab + lenvatinib Sensitive : B	pembrolizumab + lenvatinib Sensitive: B - Late Trials pembrolizumab + lenvatinib Sensitive : B
PD-L1 expression	Gastric Cancer	PD-L1 expression	Gastric Cancer	pembrolizumab + lenvatinib Sensitive: C2 – Inclusion Criteria pembrolizumab + lenvatinib Sensitive : C2	pembrolizumab + lenvatinib Sensitive: C2 – Inclusion Criteria pembrolizumab + lenvatinib Sensitive : C2
PD-L1 expression	Biliary Tract Cancer	PD-L1 expression	Biliary Tract Cancer	pembrolizumab + lenvatinib Sensitive: C2 – Inclusion Criteria pembrolizumab + lenvatinib Sensitive : C2	pembrolizumab + lenvatinib Sensitive: C2 – Inclusion Criteria pembrolizumab + lenvatinib Sensitive : C2
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	lenvatinib Sensitive: C2 – Inclusion Criteria lenvatinib Sensitive : C2	lenvatinib Sensitive: C2 – Inclusion Criteria lenvatinib Sensitive : C2
DDR	Cholangiocarcinoma	DDR	Cholangiocarcinoma	lenvatinib + toripalimab-tpzi Sensitive: C3 – Early Trials lenvatinib + toripalimab-tpzi Sensitive : C3	lenvatinib + toripalimab-tpzi Sensitive: C3 – Early Trials lenvatinib + toripalimab-tpzi Sensitive : C3
PD-L1 expression	Cholangiocarcinoma	PD-L1 expression	Cholangiocarcinoma	lenvatinib + toripalimab-tpzi Sensitive: C3 – Early Trials lenvatinib + toripalimab-tpzi Sensitive : C3	lenvatinib + toripalimab-tpzi Sensitive: C3 – Early Trials lenvatinib + toripalimab-tpzi Sensitive : C3
KIF5B-RET fusion	Non Small Cell Lung Cancer	KIF5B-RET fusion	Non Small Cell Lung Cancer	lenvatinib Sensitive: C3 – Early Trials lenvatinib Sensitive : C3	lenvatinib Sensitive: C3 – Early Trials lenvatinib Sensitive : C3
PIK3R1 mutation	Hormone Receptor Positive Breast Cancer	PIK3R1 mutation	Hormone Receptor Positive Breast Cancer	lenvatinib Resistant: C3 – Early Trials lenvatinib Resistant : C3	lenvatinib Resistant: C3 – Early Trials lenvatinib Resistant : C3
USH2A mutation	Hormone Receptor Positive Breast Cancer	USH2A mutation	Hormone Receptor Positive Breast Cancer	lenvatinib Sensitive: C3 – Early Trials lenvatinib Sensitive : C3	lenvatinib Sensitive: C3 – Early Trials lenvatinib Sensitive : C3
NEFH mutation	Hormone Receptor Positive Breast Cancer	NEFH mutation	Hormone Receptor Positive Breast Cancer	lenvatinib Sensitive: C3 – Early Trials lenvatinib Sensitive : C3	lenvatinib Sensitive: C3 – Early Trials lenvatinib Sensitive : C3

PDGFR α antagonist

PDGFR α antagonist

Associations(92)

Associations
(92)